```
**SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                               AMENDED FORM 10-QSB/A**

          {x} QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2002

                                       OR

          { } TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

              FOR THE TRANSITION PERIOD FROM ________ TO __________

                         COMMISSION FILE NUMBER 1-16655

                          **AMERICARE HEALTH SCAN, INC.**
             (Exact name of registrant as specified in its charter)

                        **Florida                         65-0714523**
             (State or other jurisdiction of         (I.R.S. Employer
              incorporation or organization)        Identification No.)

                   **20 N.W. 181st Street, Miami, Florida 33169**
              (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: **(305) 770-1141**

         Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15 (d) of the Exchange Act during the past 12 months (or such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.

                                                                  YES [X] NO [ ]

         State the number of shares outstanding of each of the issuer's classes
of common equity, as of the latest practicable date:

                        Class                      Outstanding As of September 30, 2002
              Common Stock $ .001 par value                    15,115,148

                                       1
**ACCOUNTANTS' REVIEW REPORT**

To The Board of Directors and Stockholders
Americare Health Scan, Inc. and its Subsidiary

We have reviewed the accompanying consolidated balance sheet of Americare Health
Scan, Inc. and its Subsidiary as of September 30, 2002, and the consolidated
statements of operations, changes in stockholders' deficit, and cash flows for
the nine months then ended. These financial statements are the responsibility of
the Company's management.

We conducted our review in accordance with standards established by the American
Institute of Certified Public Accountants. A review of interim financial
information consists principally of applying analytical procedures to financial
data and making inquiries of persons responsible for financial and accounting
matters. It is substantially less in scope than an audit conducted in accordance
with generally accepted auditing standards, the objective of which is the
expression of an opinion regarding the financial statements taken as a whole.
Accordingly, we do not express an opinion.

Based on our review, we are not aware of any material modifications that should
be made to the accompanying financial statements for them to be in conformity
with generally accepted accounting principles.

March 19, 2003
Plantation, Florida

                                      F-1

**AMERICARE HEALTH SCAN, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                           CONSOLIDATED BALANCE SHEETS
                    SEPTEMBER 30, 2002 AND DECEMBER 31, 2001****ASSETS**

                                               September 30,   December 31,
                                                  2002            2001
                                               -------------   -------------

**CURRENT ASSETS**
   Cash                                        $          -    $      33,419
   Notes receivables- related parties                 30,222              -
                                               -------------   -------------
        TOTAL CURRENT ASSETS                          30,222          33,419
                                               -------------   -------------

**PROPERTY AND EQUIPMENT, NET OF DEPRECIATION**          94,854         113,507
                                               -------------   -------------

**OTHER ASSETS**
   Investments                                           615             615
   Patents and intangibles, net of amortization      122,789         129,251
                                               -------------   -------------
       **TOTAL OTHER ASSETS**                           123,404         129,866
                                               -------------   -------------

       **TOTAL ASSETS**                            $     248,480   $     276,792
                                               =============   =============

                          **LIABILITIES AND STOCKHOLDERS'****CURRENT LIABILITIES**
   Accounts payable                            $     147,902   $      64,573
   Accrued officer's compensation                  1,300,000       1,144,000
   Accrued expenses                                1,701,091       1,527,350
   Notes payable-stockholders                        444,296         431,127
   Notes payable-related parties                     735,743         710,622
   Convertible notes payable                         199,460         147,260
   Accrued interest- stockholder and
      related parties                              1,519,515       1,198,749
   Accrued interest- other                                -            1,221
                                               -------------   -------------
       **TOTAL CURRENT LIABILITIES**                   6,048,007       5,224,902

**STOCKHOLDERS' DEFICIT**
    Common stock, par value $.001 per
        share; 50,000,000 shares
        authorized; 15,115,148 and
        14,765,000 shares issued and
        outstanding in 2002 and 2001,
        respectively                                  15,115          14,765
    Additional paid-in capital                     1,534,368       1,355,218
    Deficit accumulated during the
       development stage                          (7,349,010)     (6,318,093)
                                               -------------   -------------
       **TOTAL STOCKHOLDERS' DEFICIT**                (5,799,527)     (4,948,110)
                                               -------------   -------------
       **TOTAL LIABILITIES AND STOCKHOLDERS'
          DEFICIT**                             $     248,480   $     276,792
                                               =============   =============

                               See accompany notes

                                      F-2

**AMERICARE HEALTH SCAN, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                      CONSOLIDATED STATEMENTS OF OPERATIONS
              FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2002 AND 2001
                      AND THE PERIOD FROM FEBRUARY 3, 1994
                      (DATE OF INCEPTION) TO SEPT 30, 2002**

                                         September 30,  September 30,
                                             2002           2001
                                         -------------  -------------

**SALES**                                    $          -   $          -

**OPERATING EXPENSES:**
   Other general and administration            307,464        257,440
   Wages                                       208,098        248,753
   Rent                                        179,075        182,406
   Research and development costs                   -              -
                                         -------------  -------------
**TOTAL OPERATING EXPENSES**                       694,637        688,599
                                         -------------  -------------

**OPERATING LOSS**                              (694,637)      (688,599)

**OTHER INCOME (EXPENSE)**
   Settlement and miscellaneous income           4,301             -
   Litigation-settlement proceeds                   -          70,243
   Litigation expense                          (22,500)            -
   Interest expense                           (318,081)      (358,806)
   Loss from investments                            -            (258)
   Loss from flood                                  -              -
   Loss on disposal of fixed asset                  -              -
                                         -------------  -------------
                                              (336,280)      (288,821)

**LOSS BEFORE INCOME TAXES**                    (1,030,917)      (977,420)

**INCOME TAX EXPENSE (BENEFIT)**                        -              -
                                         -------------  -------------

    **NET LOSS**                             $  (1,030,917) $    (977,420)
                                         =============  =============

    **NET LOSS PER SHARE**                           (0.07)         (0.07)

    **WEIGHTED AVERAGE NUMBER OF SHARES**       15,115,148     14,765,148
    **OUTSTANDING**

                               See accompany notes

                                      F-3

**AMERICARE HEALTH SCAN, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
      CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (continued)
                                December 31, 2002
 AND THE PERIOD FROM FEBRUARY 3, 1994 (DATE OF INCEPTION) TO SEPTEMBER 30, 2002**

                                                                                CAPITAL IN
                                           COMMON STOCK            EXCESS OF      DEFICIT
                                         SHARES       AMOUNT       PAR VALUE    ACCUMULATED      TOTAL
                                      ------------  ------------  ------------  ------------  ------------

**BALANCES AT DECEMBER 31, 1999**           14,761,948        14,762     1,352,885    (3,967,412)   (2,599,765)

Issuance of common shares
  for director fees (based on
  trading activity
  (based on trading activity at
   time of issuance)                         3,200             3         2,333            -          2,336

Net loss
                                                -             -             -     (1,123,574)   (1,123,574)
                                      ------------  ------------  ------------  ------------  ------------

**BALANCES AT DECEMBER 31, 2000**           14,765,148        14,765     1,355,218    (5,090,986)   (3,721,003)

Net loss
                                                -             -             -     (1,227,107)   (1,227,107)
                                      ------------  ------------  ------------  ------------  ------------

**BALANCES AT DECEMBER 31, 2001**           14,765,148        14,765      1,355,218   (6,318,093)   (4,948,110)

Issuance of common shares

  for conversion of note payable           340,000           340        169,660           -        170,000

Issuance of common shares in exchage

  for services performed                    10,000            10          9,490           -          9,500

Net Loss
                                                -             -              -    (1,030,917)   (1,030,917)
                                      ------------  ------------  ------------  ------------  ------------

BALANCES AT SEPTEMBER 30, 2002          15,115,148        15,115     1,534,368    (7,349,010)   (5,799,527)
                                      ============  ============  ============  ============  ============

                               See accompany notes

                                      F-4

**AMERICARE HEALTH SCAN, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
              FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2002 AND 2001**

                                               September 30,   September 30,
                                                   2002           2001
                                               -------------   -------------

**CASH FLOWS FROM OPERATING ACTIVITIES:**
  Net loss                                     $  (1,030,917)  $    (977,410)
  Adjustments to reconcile net loss to net cash
   used in operating activities:
      Depreciation and amortization                   25,730          32,316
      Changes in assets and liabilities:
         Other assets                                   (615)             -
         Accounts payable                             83,329         (20,375)
         Accrued officer's compensation              156,000         156,000
         Accrued expenses                            173,741         189,402
         Accrued interest-stockholder and
           related parties                           319,545         358,805

  Net cash used in operating activities             (273,187)       (261,262)
                                               -------------   -------------

**CASH FLOWS FROM INVESTING ACTIVITIES:**
  Amounts loaned to related entities                 (30,222)             -
  Loss from investment                                    -              258
  Purchase of property and equipment                      -           (1,300)
                                               -------------   -------------

  Net cash used in investing
   activities                                        (30,222)         (1,042)
                                               -------------   -------------

**CASH FLOWS FROM FINANCING ACTIVITIES:**
  Cash repaid on stockholder loan                         -          (30,000)
  Proceeds from stockholder notes                     13,169          99,373
  Proceeds from related party notes                   25,121         183,825
  Proceeds from convertible notes                     52,200          10,000
  Proceeds from the issuance of common stock         179,500              -
                                               -------------   -------------

  Net cash provided by financing
   activities                                        269,990         263,198
                                               -------------   -------------

**NET INCREASE (DECREASE) IN CASH**                      (33,419)            894

**CASH AND EQUIVALENTS, BEGINNING**                       33,419              -
                                               -------------   -------------

**CASH AND EQUIVALENTS, ENDING**                              -              894
                                               =============   =============

                               See accompany notes

                                      F-5

**AMERICARE HEALTH SCAN, INC. AND SUSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                          NOTES TO FINANCIAL STATEMENTS
                               SEPTEMBER 30, 2002****NOTE 1 - GENERAL**

The financial information included herein is unaudited; however, such
information reflects all adjustments (consisting solely of normal recurring
adjustments), which are, in the opinion of management, necessary for a fair
statement of the Company's financial position.

The information contained in these consolidated financial statements should be
read in conjunction with the Notes to the Financial Statements appearing in the
Company's Annual Report for the year ended December 31, 2001.

**NOTE 2 - GOING CONCERN**

As shown in the accompanying financial statements, the Company incurred a net
loss of $1,030,917 for the nine months ended September 30, 2002, and as of that
date, current liabilities exceeded current assets by $6,017,785 and its total
liabilities exceeded its total assets by $5,799,527. Those factors, as well as
the need to obtain additional financial resources, create an uncertainty about
the Company's ability to continue as a going concern. Management of the Company
is developing a plan to finance its continuing research and development
activities through the issuance of debt or equity securities. The ability of the
Company to continue as a going concern is dependent on the success of the plan
or the continued support of the Company's major shareholder. The financial
statements do not include any adjustments that might be necessary if the Company
is unable to continue as a going concern.

**NOTE 3 - RECENT PRONOUNCEMENT**

During 2002, the Company implemented Statement of Financial Accounting Standards
(SFAS) No. 144 "Accounting for the Impairment or Disposal of Long-Lived Assets"
which supercedes SFAS No. 121, "Accounting for the Impairment of Long-Lived
Assets and for Long-Lived Assets to Be Disposed Of". The Company does not expect
the adoption of this statement to have a material impact on its financial
statements.

**NOTE 4 - LITIGATION**

The Corporation is involved in several pieces of litigation, which are set forth
below. In 1995, Americare Biologicals, Inc., Joseph P. D'Angelo, Americare
Transtech, Inc., and International Medical Associates, Inc. (the "Plaintiffs")
filed suit in Florida state court (Broward County) against Technical Chemicals
and Products, Inc. ("TCPI") and its then chairman Jack Aronowitz, Simplex
Medical Systems, Inc. ("Simplex") and its then officers Henry B. Schur and
Nicholas Levandoski, and Analyte Diagnostics, Inc. ("Analyte"), claiming
misappropriation of trade secrets and interference with business relationships
relating to the Company's proprietary Saliva Collection System and HIV Saliva
Test. On January 25, 1999, judgment was entered in favor of Plaintiffs against
Schur, Levandoski, TCPI, Aronowitz, Simplex and Analyte. On appeal, $4.3 Million
of the $4.8 Million in damages awarded against Schur, Levandoski, Aronowitz and
TCPI was affirmed. Only the $500,000 judgment against Aronowitz was reversed. In
December 2000, the appeal bond that had been posted by TCPI was ordered paid,
and Americare Biologicals, Inc. received $388,890. Nicholas Levandoski, against
whom Americare Biologicals, Inc. and Americare Transtech, Inc. had judgments
totaling $1,000,000, filed for Chapter 7 Bankruptcy protection in 2000. The
Plaintiffs are currently attempting to collect the $3,000,000 judgment against
Schur. Of the $3 million judgment against Schur, $1 million each was awarded to
Americare Biologicals, Inc., Americare Transtech, Inc., and Dr. D'Angelo. Mr.
Schur and Mr. Levandoski are currently incarcerated, making collection
difficult.

                                      F-6

**AMERICARE HEALTH SCAN, INC. AND SUSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                          NOTES TO FINANCIAL STATEMENTS
                               SEPTEMBER 30, 2002**

In 1997, Americare Diagnostics, Inc., Joseph P. D'Angelo, Americare Transtech,
Inc., and International Medical Associates, Inc., (the "Plaintiffs") filed suit
in federal court (Southern District of Florida) against TCPI and its then
chairman Jack Aronowitz, and Simplex and its then officers Henry B. Schur and
Nicholas Levandoski, claiming patent infringement and misappropriation of trade
secrets relating to the Company's patented biological fluids constituent
analysis system. A confidential settlement agreement was reached with TCPI on
February 3, 2001, which resolved all litigation between TCPI and the Plaintiffs.
TCPI, which filed a voluntary Chapter 11 bankruptcy petition on July 3, 2001
(subsequently converted to Chapter 7), still owes approximately $38,700 under
the settlement agreement. The Company settled with Simplex on June 26, 2001. The
Company has filed a proof of claim as a creditor in the bankruptcy proceedings,
which it is closely monitoring.

In 1997, Henry B. Schur filed suit against Dr. D'Angelo, Americare Transtech,
Inc., Americare Health Scan, Inc., Americare Biologicals, Inc., International
Medical Associates, Inc., and Americare Diagnostics, Inc. asserting claims
relating to the tape recording and use of a conversation Schur had with Dr.
D'Angelo on the street. Currently the case is not moving forward due to the
incarceration of Mr. Schur.

TCPI and Aronowitz, in 1999, filed action in federal court (Southern District of
Florida) against the Company, Joseph P. D'Angelo, and Creative Connections,
Inc., claiming that Plaintiffs had engaged in false advertising in violation of
the Lanham Act, and common law defamation. All claims by TCPI were dismissed
pursuant to a settlement agreement in February 2001. On August 2, 2001, Mr.
Aronowitz filed a voluntary dismissal without prejudice of his Lanham Act and
defamation claims and the company is in the process of determining whether to
seek attorney's fees and costs from Aronowitz.

In 1999, the Company, Americare Biologicals, Inc., and Joseph P. D'Angelo
("Plaintiffs") filed a defamation suit in Florida state court against TCPI, Jack
Aronowitz and Robert Zelinka. Plaintiffs settled with TCPI in February 2001. On
July 27, 2001, Plaintiffs entered into a confidential settlement with Zelinka.
The Court granted the Companies Mortion to Strike and Enter Default against Mr.
Aronowitz. A hearing on the issue of damages is set for April 24, 2002.

In 1999, the Company, Americare Biologicals, Inc., and Joseph P. D'Angelo
("Plaintiffs") filed a defamation lawsuit in Florida state court against Warren
Vitale. The Plaintiff is currently conducting discovery and hopes to have its
Motion for Summary Judgment heard after further discovery is taken.

In November 1999, the building in which the Company is a tenant sustained
substantial damage as a result of water leakage from a coffee machine that had
been installed and maintained by Perfect Choice Coffee, Inc. Some of the
Company's equipment and work in process was damaged and/or destroyed. The
landlord's insurance company went bankrupt and did not cover the losses. As a
result, the Company, its landlord, and related entities jointly filed two
separate lawsuits against the underwriter (Jackson Agency, Inc.) and the coffee
machine company (Perfect Choice Coffee, Inc.) seeking to recover their losses.
Consolidated discovery is ongoing and this matter is currently not set for
trial.

                                      F-7

**AMERICARE HEALTH SCAN, INC. AND SUSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                          NOTES TO FINANCIAL STATEMENTS
                               SEPTEMBER 30, 2002**

Henry B. Schur, a former employee of the Company, has filed an interference
claim with the U.S. Patent and Trademark Office alleging that he, not Dr.
D'Angelo, is the principal inventor of the Company's Saliva Collection System.
In view of the January 1999 court judgment that Schur misappropriated trade
secrets relating to the Company's Saliva Collection System, and Schur's
assignment of all rights, title or interest in the Saliva Collection System to
Americare Transtech, Inc., the Company believes that its exclusive ownership of
the technology has been established.

In the normal course of business, the Company is involved in various disputes,
claims and/or litigation. Given the current financial condition of the Company,
the resolution of any of the above-discussed matters against the Company by
judgment or the award of attorney's fees and costs could have a material adverse
impact on the consolidated financial statements.

**NOTE 5 - SUBSEQUNT EVENT**

Shares have been issued during the fourth quarter of 2002 as a result of the
February 28, 2002, stockholders approval of the Plan of Merger under which
Americare Technologies, Inc., Americare International Diagnostics, Inc. and
Americare Diagnostics, Inc. will merge with Americare Health Scan, Inc.
Americare Health Scan, Inc., will be the surviving corporation.

                                      F-8

**ITEM 1:  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
         OF OPERATIONS

RESULTS OF OPERATION

NINE MONTHS ENDED SEPTEMBER 30, 2002**

The Company has had no revenues from operations since its inception.  Our only
income has been from litigation settlements and collection of judgments.

As of September 30, 2002 the Company's current liabilities exceeded current
assets and this fact, and the need for additional financing, creates an
uncertainty about the Company's ability to continue as a going concern. The
Company is currently developing a plan to finance its operations through the
sale of products, and the issuance of debt and/or equity securities. The ability
of the Company to continue as a going concern is dependent on the success of the
plan, the continued financial support from Dr. D'Angelo, his family, related
entities, and other individuals and the Company's ability in the future to
generate revenues from the marketing and sale of its technology, products or
services.

There have been no significant research and development expenditures since 1999,
except for minimal research by Dr. D'Angelo that he financed with his personal
funds. The primary reason that there have been no Company research and
development expenses for the past few years is that there have not been
sufficient funds available to finance both the litigation in which the Company
has been involved and research and development. Management's focus during this
period has been protecting the Company's intellectual property.

Operation expenses decreased for the nine months ended September 30, 2002 and
the period from September 30, 2001 respectively, primarily due to the reduction
of costs in connection with litigation which is in the process of being settled.
All of the Company's activities for the nine months ended September 30, 2001 and
2002 were financed with loans from the Company's President, Dr. D'Angelo, his
family, and affiliated entities and other individuals. Interest expense of
$318,081, relating to those and previous loans from related parties and other
individuals and accrued expenses payable to related parties, accrued for nine
months ended September 30, 2002.

As of September 30, 2002, the Company has no cash reserves, and total assets
were $248,480. In addition total liabilities as of September 20, 2002 were
$6,048,007. This debt includes the demand notes totaling $2,600,000 plus
interest, due and payable to Dr. D'Angelo, his family and affiliated entities to
secure loans. All accrued expenses total $1,701,091, accrued interest to
shareholders and related parties total $1,519,515, as reflected in the Amended
Balance Sheet of September 30, 2002. Payment of the notes can be demanded at any
time at the discretion of the holder.

The Company has not been profitable, and has had negative cash flow from
operations in part due to substantial expenditures for litigation to protect its
intellectual property and proprietary technology. For the past several years
this litigation has taken up the vast majority of management's time and energy.

Management's plan for the future is to focus on raising funds and obtaining
orders for the Company's Saliva HIV Test and other technologies so that adequate
management, technical and other personnel can be hired, and laboratory equipment
and supplies purchased for the Company to perform remaining research and
development on its products. Such funds would also enable the Company to pursue
FDA approval of its products and expand marketing efforts. These activities will
require tens of millions of dollars.

                                       2
**PART II: OTHER INFORMATION

ITEM 1: LEGAL PROCEEDINGS:**

The Corporation is involved in several pieces of litigation, which are set forth
in the Corporation's Form 10KSB. On July 15, 2002 the Company entered a
settlement agreement with Market Surveys International in the case styled
Americare Health Scan, Inc. v. Market Surveys, Int'l., Dade County Circuit Court
Case No. 02-15173 CA 27. Pursuant to the agreement the Company allowed Market
Surveys to retain 11,500 shares of free trading stock in the Company as
compensation for partial performance of the marketing agreement. There has been
no new legal proceedings other than those listed on the Form 10KSB.

The Corporation's annual report on Form 10-KSB under Section 13 of the
Securities and Exchange Act of 1934 was filed April 10, 2002.

**ITEM 2: CHANGES IN SECURITIES:**

There are approximately 509 shareholders of record of the Company's common
stock, and 15,115,148 outstanding shares of common stock currently issued and,
of those shares 12,638,476 are restricted. Mr. Anthony Iemma elected to exercise
his conversion rights under the Promissory Notes Loan Agreement dated February
1, 2002. Mr. Iemma elected to convert 340,000 restricted shares in the Company.
Josh Ward was given 10,000 shares to compensate him for webmaster services for
the Company.

**ITEM 3: DEFAULTS UPON SENIOR SECURITIES:**

None.

**ITEM 4: SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS**

The Company had no matters submitted to a vote of security holders during this
Quarter.

**ITEM 5: OTHER INFORMATION:**

The Board of Directors approved the appointment of Eugene D'Angelo as a member
of the Board of Directors at the Board Meeting held on April 19, 2002.  Eugene
D'Angelo replaces former Board member Eugene L. Foltuz who resigned.

**ITEM 6: EXHIBITS & REPORTS:**

        Exhibits

        99.1 Certification of Chief Executive Office and Chief Financial Officer

                                       3
**SIGNATURE**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.

Dated: April 15, 2003                   /s/ Dr. Joseph P. D'Angelo
                                          -----------------------------------
                                            Dr. Joseph P. D'Angelo
                                            President
```